Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2´, 2´- Difluorodeoxycytidine (DHA-dFdC).

about

Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2´, 2´- Difluorodeoxycytidine (DHA-dFdC).

Item

http://www.wikidata.org/entity/Q52779258

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Preclinical Evaluation of the ...... luorodeoxycytidine (DHA-dFdC).

@en

Preclinical Evaluation of the ...... luorodeoxycytidine (DHA-dFdC).

@nl

type

Item

label

Preclinical Evaluation of the ...... luorodeoxycytidine (DHA-dFdC).

@en

Preclinical Evaluation of the ...... luorodeoxycytidine (DHA-dFdC).

@nl

prefLabel

Preclinical Evaluation of the ...... luorodeoxycytidine (DHA-dFdC).

@en

Preclinical Evaluation of the ...... luorodeoxycytidine (DHA-dFdC).

@nl

P1476

Preclinical Evaluation of the ...... fluorodeoxycytidine (DHA-dFdC)

@en

P2093

Christopher A Jolly

http://www.w3.org/2001/XMLSchema#string

Rick A Finch

http://www.w3.org/2001/XMLSchema#string

Solange Valdes

http://www.w3.org/2001/XMLSchema#string

Wallace B Baze

http://www.w3.org/2001/XMLSchema#string

Zhengrong Cui

http://www.w3.org/2001/XMLSchema#string

P2860

Omega-3 Fatty Acids in Modern Parenteral Nutrition: A Review of the Current Evidence

Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies.

Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.

The targeting mechanism of DHA ligand and its conjugate with Gemcitabine for the enhanced tumor therapy

N-3 fatty acids, cancer and cachexia: a systematic review of the literature.

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

P304

1224-1232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-017-2139-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Youssef W Naguib

P577

2017-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28352993

http://www.w3.org/2001/XMLSchema#string

P932

5488709

http://www.w3.org/2001/XMLSchema#string